second quarter and to thank call XXXX joining our afternoon, you welcome you results. us Good Shockwave's pleased to I'm Thanks, to review for Debbie. everyone, today.
It that the witnessed end the to the quarter reported second second fourfold have increase see is in our the and at trends and quarter We million for revenue in encouraging this first the the year, over of $X.X which positive second up XXXX prior XXXX, quarter. through million over $XX has been was of of we a of quarter quarter XXXX. continued
that we the U.S came from to MX As products growth continues role catheter potential the population. -- has catheter. internationally of thesis a geographies mix first our play coronary above-the-knee global the lithotripsy saw in a addressing to CX from and in intravascular quarter, and our significant patient peripheral This our confirm principally meaningful in
range Based the the now details on later we in summer in results peripheral of expect and seasonality XXXX million of will coronary call. more to $XX full-year to the encouraging $XX predictable despite million. Dan be international revenue and procedures, the U.S for provide of these financial
been there any many. and Before balloons a that impact. what had little has has I their position use to the turning that Dan, quarter drug-coated highlights FDA's relative the has from call Since share. to the like or few however, would to for DCBs by it answer the I mind want my no start that topic is and of short impact top if to to addressing And Shockwave. are on it
we will publicly. their FDA when positively feeling DCBs in position that and was assume While general the that be in the less than negative update their most were the of back were they FDA panel favor meetings inconclusive, recent somewhat they in June statements by
in usage but in meaningful a recent had rather usage that the past it We continue was to the reduction believe been XXXX. the DCBs DCB be months, lower been higher will of than has months in future In it than in there an be six largely witness not usage, to utilization. been suggests even completely stopped continue that to will sites us uncorrelated volume did and DCB has IVL DCBs. yet and that we impact usage have with obvious This using IVL on
Organizationally to our and great new existing maintaining and educating on continued we’ve new users concentrate to on outcomes, adding focus have efforts this elected saga within sites. sites not
Our were right recent things on. to results focus suggest these that the
DCB angioplasty drug-coated III our of global the challenges While disrupt randomized the impact balloon. benefits study balloon is affect our they did did our Shockwave an to of not drug-coated have post-market followed business which the by evaluating arm versus PAD on prior study,
in both of the arms suspended study include trial FDA we of that enrollment June. meetings DCBs, had Given the panel the pending
principal -- informed with the FDA require studies. restart and and reviewed will Once DCB documents study for additional We've our study. we results final will risk the the position, revise language FDA consents investigators FDA anticipate and our information panel patient we’ve
there patient III arm a reminder, arms of are randomized discussed the a X,XXX registry. The trial. As and patient two Pad just XXX
are arm incidence we we’ve a that that to patients below a are anticipate expand This beyond knee set protocol to patients registry patients Given will enough enrolled ensure date, next revised the over that to create to XXX but data the our very for a few this to population important now accumulate able expansion X,XXX of planning meaningful planning we is sites we calcification. this in stages, still complex months. high has in be the at
enrolled XXX our bringing patient quarter, were XXXX. by we ultimately that studies, second in disrupt PAD the Turning the sites quarter the on June in study, patient total of complete U.S IIII, and as quarter the Of study track remain XX our end in activated will XX. of patients to the enrollment XX enrollment of the participate to second XX our XXX IDE coronary to
device use our in countries of and disrupt PMDA studies. approval with combined In authority or share we gain coronary CAD data III the discussions and the forward to pharmaceutical move IV from CAD lithotripsy to on and intravascular for continue Japan, medical based
the trial reminder, is notification a XX or pre-market a IV study patient As CTN. CAD clinical
in requiring follow-up. PMDA mid-XXXX ultimate We Japan, in enrollment this which a originally since than initiate approval later is expect one-year is to bit with planned fall
and We're trials. where IVL on II European coronary to forward post-approval TCT to the largest comment presentation for been will CAD represent final from look We data XXX data accepted our patient One set has with coronary we've registry many study and capabilities progress the opportunities conferences data technology been investigators recent share have and clinical of date. to Shockwave's our on pleased the the made have there to the generated. front
and with There biggest trading quarter our Shockwave EuroPCR XX for the was witnessed team. and this Abiomed was the events. subject roughly event Shockwave our room cases, of four past only at of intravascular the including a audiences presentations live standing at whirlwind combined many we were sessions, Shockwave lithotripsy
Belfast Congress types, to be by a PCR at X,XXX case One the of the presentations was voted the at IVL in best this cases was year by flatter from this of that that was quite different least. of presented case all out physician presentation and
a we to addition, Coronary toughest by be a Top synergistically judged and to The their a were hosted patient. of very Shock submit Rotablator winner ask customers Shockwave challenging Shockwave In IVL where manage was great cases to a physicians. contest Case where panel used we case
customers international to Our seem really enjoy event. this
PCR year. was into how and versatility great demonstrated year's coronaries their integrated European intravascular coronary in have our lithotripsy just practice the system of This the one rapidly in of Shockwave's customers a representation
cases CX, conferences addition including various SBS, at EuroPCR, other as great as In conferences Shockwave to this And of also the we symposia was [ph] well many [indiscernible]. TBT multiple quarter. NCBH, had used XX visibility live in
to where of not our our sessions, have frequent a symposium or who coronary new peripheral in Impella coronary access We were concept ordinarily focused who the experiment the content, attended physicians expand practitioners for first with of placement. group TBT but using iliacs are session. held Shockwave TBT any users does bore TAVR peripheral or we large on calcified the a was so rather or the strictly not
shelf, complements the our And increasingly symposium we roughly tracking using nicely XXXX. bore on where access staffing field with over our large Europe U.S iliac course strategy our presence front, the on are many XX% by entry broaden focus Also direct Shockwave's applications. peripheral U.S to to efforts our other commercial goal and once accounts. expand in of are consistently point commercial This as at we the
We sales try vast U.S., while Internationally, selling us in to We're Shockwave. adoption many now encouraging in of regions four, we have local we and have help getting countries and sites management even XX in to to majority which started. the teams. countries, the also have more witnessed we're support and just specialists yet added two brings so our physicians
conferences Abiomed. partnerships iliac and frequency meeting customers. We are continue will advisory with multiple an field-based also to the Impellas that conducted jointly aware see The more IVL by progress training safely be sessions use will Shockwave sell. our We in sell local collaboration presence Abiomed Shockpella more piloting held joint expand MXs locally how and and of at should anticipate in training become calcium, approach We to at Impella there of increasing and in the to conferences. we refine should medical more to can place June, Impellas easily steady a they board users arteries extension the the
are for partnership course. Shockwave, from of There benefits additional this
train to cases or The our users with And not one Impella #state coronaries. we vast choose help use access TAVR Impella of even femoral do access. many also of users Abiomed those alternative First, also can treat bore for IVL where large if Shockwave is customers avoid coined. majority has
launch of our be of XXXX. in and exposure advance So there awareness will meaningful well coronary Shockwave U.S in
clinical the in product, to and to below the response out SX in remain our will sizes smaller launch device, to fully year. this encouraged of roll by our while highly fourth launch SX limited the we're respect quarter With mode, which we prepare knee still to
A on property. quick note intellectual
and three seen, Institute Patent have may our Trademark decided patents. the you or the As to and IPRs and Board has U.S officially Appeal of PTAB
to the the patent trial, the these us as IPRs of unfortunately the process business not and our broad decisions we strategy portfolio impact move and and requires out quite of IPR on remain do are to draw While forward. we concerned confident in our about viability go
me to team their with operations. Behind and scenes, the our has performance. dedication impressed really Turning
increase almost our shift to and had daily is clean just output. our has completed. Our in our on new in move fire room a second space with matching Clara first and the up that team twofold we now fully January. since we shift production, operations We’ve facility double And been a Santa running
extremely shifts the managed tests The of systems strength passed which sign top a our all and European of team inspections, preparing testament was of any and body and processes. flying complimentary the to to Together the successfully risk our both is from Again, great FDA good the for audits and we just least. the colors. move. and preparations with steady on improvement move strong associated without our a of of team continued Despite production in disruptions inspections issues. integrity move quality say FDA we to capabilities as were this, were notified On the and we
in with our And also facility we grown production have sales, team. larger conjunction increases, increased in
As organizational had we of June board year employees, XX XXX R&D, including from added across of XX, and clinical regulatory we such areas management, over as and key program marketing increase the the beginning sales, -- the operations. of an
as announced Tada delighted as Keith are the also of General to We Medical Haj Counsel both Officer. and addition have recently Chief Dawkins
to opportunities in front to to best that will capabilities position We in of enhance ensure take of are us. the possible meaningful continue advantage our we the
would I call like Dan. the that, to With to turn
